Licensing · Global (LMICs) · Announced 16 Nov 2026

Gilead Sciences → Dr. Reddy's Laboratories

Gilead granted Dr. Reddy's a royalty-free voluntary licence to manufacture and supply investigational obeldesivir for Ebola Bundibugyo post-exposure prophylaxis in 127 mainly low- and lower-middle-income countries, including African outbreak countries.

Parties: Gilead Sciences (United States) → Dr. Reddy's Laboratories (India)

Deal type
Licensing
Value
Royalty-free
Territory
127 countries, primarily low- and lower-middle-income, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak
Therapeutic area
Infectious Disease
Asset
obeldesivir
Announced
16 Nov 2026

Our analysis

Why this matters

On 16 November 2026 Gilead Sciences announced royalty-free voluntary licensing agreements with Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories for obeldesivir, an investigational oral antiviral under study for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). The licensed territory is 127 countries, primarily low- and lower-middle-income, including all African countries reporting cases in the current outbreak.

The licences were signed ahead of results from EBO-PEP, a partner-led Phase 3 randomised, placebo-controlled trial coordinated by ALIMA. Obeldesivir is not approved anywhere; licensed manufacture and supply depend on clinical data and regulatory authorisations.

The full analysis is free to read with a work email on this page.

Source: Gilead Sciences press release

More deals involving Gilead Sciences or Dr. Reddy's Laboratories

Latest deals

All Global (LMICs) deals → · All licensing deals → · Browse all emerging-market pharma deals →